FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806146840> ?p ?o ?g. }

• W2806146840 abstract "Sunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma (MRCC) setting at the dose of 50 mg daily for 4 weeks followed by a pause of 2 weeks. Due to toxicity, this standard schedule (50 mg daily 4/2) can induce up to 50% of sunitinib dose modification (reduction and/or interruption). The current recommendation in such case is to reduce the dose to 37.5 mg per day (standard schedule 4/2). Recent data highlight an alternative schedule: 2 weeks of treatment followed by 1 week of pause (experimental schedule 2/1). The SURF trial is set up to evaluate prospectively experimental schedule 2/1 when toxicity occurs. This article displays the key elements of the study protocol.SURF [NCT02689167] is a prospective, randomized, open-label phase IIb study. Patients are included at sunitinib initiation while receiving standard schedule 4/2 (50 mg daily) according to the marketing authorization indication. When a dose adjustment of sunitinib is required, patients are randomized between standard schedule 4/2 (37.5 mg daily) and experimental schedule 2/1 (50 mg daily). Key eligibility criteria are the following: patients with locally advanced inoperable or MRCC who are starting first-line treatment with sunitinib, with histologically or cytologically confirmed renal cancer clear cell variant or with a clear cell component, and with Karnofsky performance status ≥70%. The primary objective is to assess the median duration of sunitinib treatment (DOT) in each group. The key secondary objectives are progression-free survival, overall survival, time to randomization, objective response rate, safety, sunitinib dose intensity, health-related quality of life, and the description of main drivers triggering randomization. We hypothesized that experimental schedule 2/1 would result in an improvement in median DOT from 6 to 8.5 months. It was estimated that 112 patients would be needed in each arm during 24 months. In order to take into account the possibility of treatment discontinuation before randomization, 248 patients are necessary.The SURF trial is asking a pragmatic question adapted to the current practice on what is the best way to adapt sunitinib when treatment-related adverse events occur. The results of the SURF trial will bring high-value data to support the use of an alternative schedule in sunitinib treatment.ClinicalTrials.gov, NCT02689167 . Registered on 26 February 2016." @default.
• W2806146840 created "2018-06-13" @default.
• W2806146840 creator A5014323516 @default.
• W2806146840 creator A5033357246 @default.
• W2806146840 creator A5038095307 @default.
• W2806146840 creator A5041153330 @default.
• W2806146840 creator A5041556432 @default.
• W2806146840 creator A5059531510 @default.
• W2806146840 creator A5065018863 @default.
• W2806146840 creator A5067565814 @default.
• W2806146840 creator A5067828312 @default.
• W2806146840 creator A5073549134 @default.
• W2806146840 creator A5079351370 @default.
• W2806146840 creator A5080127868 @default.
• W2806146840 date "2018-04-12" @default.
• W2806146840 modified "2023-09-27" @default.
• W2806146840 title "Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial" @default.
• W2806146840 cites W1946476244 @default.
• W2806146840 cites W2019607817 @default.
• W2806146840 cites W2061581498 @default.
• W2806146840 cites W2084411902 @default.
• W2806146840 cites W2107103442 @default.
• W2806146840 cites W2115125611 @default.
• W2806146840 cites W2116949558 @default.
• W2806146840 cites W2117125017 @default.
• W2806146840 cites W2167571044 @default.
• W2806146840 cites W2207224549 @default.
• W2806146840 cites W2473786944 @default.
• W2806146840 cites W2507659807 @default.
• W2806146840 cites W2530419161 @default.
• W2806146840 cites W2602047891 @default.
• W2806146840 cites W2603963110 @default.
• W2806146840 doi "https://doi.org/10.1186/s13063-018-2613-8" @default.
• W2806146840 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5898055" @default.
• W2806146840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29650037" @default.
• W2806146840 hasPublicationYear "2018" @default.
• W2806146840 type Work @default.
• W2806146840 sameAs 2806146840 @default.
• W2806146840 citedByCount "8" @default.
• W2806146840 countsByYear W28061468402018 @default.
• W2806146840 countsByYear W28061468402019 @default.
• W2806146840 countsByYear W28061468402020 @default.
• W2806146840 countsByYear W28061468402021 @default.
• W2806146840 countsByYear W28061468402022 @default.
• W2806146840 crossrefType "journal-article" @default.
• W2806146840 hasAuthorship W2806146840A5014323516 @default.
• W2806146840 hasAuthorship W2806146840A5033357246 @default.
• W2806146840 hasAuthorship W2806146840A5038095307 @default.
• W2806146840 hasAuthorship W2806146840A5041153330 @default.
• W2806146840 hasAuthorship W2806146840A5041556432 @default.
• W2806146840 hasAuthorship W2806146840A5059531510 @default.
• W2806146840 hasAuthorship W2806146840A5065018863 @default.
• W2806146840 hasAuthorship W2806146840A5067565814 @default.
• W2806146840 hasAuthorship W2806146840A5067828312 @default.
• W2806146840 hasAuthorship W2806146840A5073549134 @default.
• W2806146840 hasAuthorship W2806146840A5079351370 @default.
• W2806146840 hasAuthorship W2806146840A5080127868 @default.
• W2806146840 hasBestOaLocation W28061468401 @default.
• W2806146840 hasConcept C126322002 @default.
• W2806146840 hasConcept C126894567 @default.
• W2806146840 hasConcept C143998085 @default.
• W2806146840 hasConcept C197934379 @default.
• W2806146840 hasConcept C2777288759 @default.
• W2806146840 hasConcept C2777472916 @default.
• W2806146840 hasConcept C2778375690 @default.
• W2806146840 hasConcept C2779490328 @default.
• W2806146840 hasConcept C2781413609 @default.
• W2806146840 hasConcept C29730261 @default.
• W2806146840 hasConcept C535046627 @default.
• W2806146840 hasConcept C71924100 @default.
• W2806146840 hasConceptScore W2806146840C126322002 @default.
• W2806146840 hasConceptScore W2806146840C126894567 @default.
• W2806146840 hasConceptScore W2806146840C143998085 @default.
• W2806146840 hasConceptScore W2806146840C197934379 @default.
• W2806146840 hasConceptScore W2806146840C2777288759 @default.
• W2806146840 hasConceptScore W2806146840C2777472916 @default.
• W2806146840 hasConceptScore W2806146840C2778375690 @default.
• W2806146840 hasConceptScore W2806146840C2779490328 @default.
• W2806146840 hasConceptScore W2806146840C2781413609 @default.
• W2806146840 hasConceptScore W2806146840C29730261 @default.
• W2806146840 hasConceptScore W2806146840C535046627 @default.
• W2806146840 hasConceptScore W2806146840C71924100 @default.
• W2806146840 hasFunder F4320307765 @default.
• W2806146840 hasIssue "1" @default.
• W2806146840 hasLocation W28061468401 @default.
• W2806146840 hasLocation W28061468402 @default.
• W2806146840 hasLocation W28061468403 @default.
• W2806146840 hasLocation W28061468404 @default.
• W2806146840 hasLocation W28061468405 @default.
• W2806146840 hasOpenAccess W2806146840 @default.
• W2806146840 hasPrimaryLocation W28061468401 @default.
• W2806146840 hasRelatedWork W1998081924 @default.
• W2806146840 hasRelatedWork W2072245035 @default.
• W2806146840 hasRelatedWork W2084340632 @default.
• W2806146840 hasRelatedWork W2155969715 @default.
• W2806146840 hasRelatedWork W2165094466 @default.
• W2806146840 hasRelatedWork W2544140097 @default.
• W2806146840 hasRelatedWork W3151554875 @default.
• W2806146840 hasRelatedWork W4205243027 @default.
• W2806146840 hasRelatedWork W4226201642 @default.

• next